RINVOQ 30 mg upadacitinib

RINVOQ is a prescription medication developed by the global biopharmaceutical company AbbVie. It contains the active substance upadacitinib and is primarily used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.

AbbVie, the manufacturer, was formed in 2013 as a spin-off from Abbott Laboratories. While the company is headquartered in the United States, its manufacturing network for advanced biologics and small molecules like RINVOQ spans several countries, including major production hubs in Ireland and various facilities across the US. In the Iberian market, the product is distributed by AbbVie's local subsidiaries in Portugal (AbbVie, Lda.) and Spain (AbbVie Spain, S.L.U.), ensuring compliance with local medical regulations.